Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas
  
lung cancer
Akeso/Summit bispecific antibody demonstrates PFS in lung cancer setting • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Therapy Areas